Skip to main content
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Features
Assistant
AI grounded in research
Search
Full-text citation search
Collections
Organize and monitor papers
All Features →
Integrations
MCP
Connect AI agents to Scite
API
Programmatic data access
Holdings
Full-text via your library
Zotero Plugin
Citation data in Zotero
Browser Extension
Citation badges anywhere
All Integrations →
Data
Rankings
Pricing
Log In
Start Free Trial
Elke Jäger
Sign up to set email alerts
506
Publications
16,091
Citation Statements Received
7,675
Citation Statements Given
How they've been cited
21,101
706
15,270
115
How they cite others
9,365
300
7,352
23
Affiliations
Krankenhaus Nordwest
,
Ludwig Cancer Research
Publications
Order By: Most citations
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial
Al‐Batran
1
,
Homann
2
,
Pauligk
3
et al.
2019
The Lancet
2,797
105
2,169
31
Get access via publisher
Add to collection
Cite
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition
Nelde
1
,
Bilich
2
,
Heitmann
3
et al.
2020
Nat Immunol
Abstract
Show
664
77
820
3
Get access via publisher
Add to collection
Cite
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial
Al‐Batran
1
,
Hofheinz
2
,
Pauligk
3
et al.
2016
The Lancet Oncology
768
37
561
12
Get access via publisher
Add to collection
Cite
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
Stockert
1
,
Jäger
2
,
Chen
3
et al.
1998
Abstract
Show
664
20
558
3
Get access via publisher
Add to collection
Cite
Anti-CCR4 mAb selectively depletes effector-type FoxP3
+
CD4
+
regulatory T cells, evoking antitumor immune responses in humans
Sugiyama
1
,
Nishikawa
2
,
Maeda
3
et al.
2013
Proc. Natl. Acad. Sci. U.S.A.
Abstract
Show
648
20
558
0
Get access via publisher
Add to collection
Cite
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
Jäger
1
,
Chen
2
,
Drijfhout
3
et al.
1998
Abstract
Show
689
4
493
3
Get access via publisher
Add to collection
Cite
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
Al‐Batran
1
,
Hartmann
2
,
Probst
3
et al.
2008
JCO
Abstract
Show
784
20
453
3
Get access via publisher
Add to collection
Cite
Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE3 and presented by HLA‐A1
Marchand
1
,
van Baren
2
,
Weynants
3
et al.
1999
Int. J. Cancer
Abstract
Show
302
5
360
0
Get access via publisher
Add to collection
Cite
1
2
3